Aclaris Therapeutics Inc (ACRS)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Neal S. Walker
Employees:
70
SUITE 400, 101 LINDENWOOD DRIVE, MALVERN, PA 19355
484-321-5554

Aclaris Therapeutics, Inc. develops novel drug candidates for immune-inflammatory diseases in the United States. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa.

Data derived from most recent annual or quarterly report
Market Cap 1.127 Billion Shares Outstanding66.683 Million Avg 30-day Volume 388.021 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.25
Price to Revenue44.6583 Debt to Equity0.0 EBITDA-82.864 Million
Price to Book Value4.7738 Operating Margin-356.034 Enterprise Value801.408 Million
Current Ratio12.965 EPS Growth0.192 Quick Ratio12.566
1 Yr BETA 1.0793 52-week High/Low 18.96 / 9.84 Profit Margin-349.2638
Operating Cash Flow Growth-49.2099 Altman Z-Score9.8681 Free Cash Flow to Firm -57.384 Million
Earnings Report2023-02-23
View SEC Filings from ACRS instead.

View recent insider trading info

Aclaris Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ACRS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ACRS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-01-20 by POWELL ANDREW KENNETH WILLIAM
  • 3: filed on 2023-01-06 by BALTHASER KEVIN
  • 4: filed on 2022-12-16 by MONAHAN JOSEPH
  • 4: filed on 2022-11-14 by SCHIFF ANDREW N
  • 4: filed on 2022-10-26 by SCHIFF ANDREW N
  • 4: filed on 2022-10-19 by SCHIFF ANDREW N
  • 4: filed on 2022-10-19 by MONAHAN JOSEPH
  • 4: filed on 2022-10-11 by SCHIFF ANDREW N
  • 4: filed on 2022-10-06 by SCHIFF ANDREW N
  • 4: filed on 2022-08-02 by MANION DOUGLAS J.

    • Events (8k)

  • 8-K: filed on 2023-01-09:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-06:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-12-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-11-22:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-11-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-01:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-03:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-14:
    Item 7.01: Regulation FD Disclosure

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    45 Thousand total shares from 4 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    WALKER NEAL

    • Director
    		 1,205,763 2023-01-03 5

    BALTHASER KEVIN CHIEF FINANCIAL OFFICER

    • Officer
    		 700 2023-01-01 1

    MONAHAN JOSEPH CHIEF SCIENTIFIC OFFICER

    • Officer
    		 96,579 2022-12-15 6

    SCHIFF ANDREW N

    • Director
    		 434,455 2022-11-10 7

    POWELL ANDREW KENNETH WILLIAM

    • Director
    		 9,856 2022-11-08 2

    MANION DOUGLAS J. PRES AND COO

    • Officer
    		 280,100 2022-08-01 2

    CAWKWELL GAIL CHIEF MEDICAL OFFICER

    • Officer
    		 270,000 2022-07-01 2

    MILANO VINCENT

    • Director
    		 20,257 2022-06-02 1

    GOWEN MAXINE

    • Director
    		 28,051 2022-06-02 1

    REASONS BRYAN M.

    • Director
    		 39,822 2022-06-02 1

    MEHRA ANAND

    • Director
    		 54,454 2022-06-02 1

    MOLINEAUX CHRISTOPHER P.

    • Director
    		 47,504 2022-06-02 1

    HUMPHRIES WILLIAM D.

    • Director
    		 39,822 2022-06-02 1

    RUFFO FRANK CHIEF FINANCIAL OFFICER

    • Officer
    		 201,883 2022-03-10 3

    LOEROP JAMES CHIEF BUSINESS OFFICER

    • Officer
    		 200,000 2022-02-01 0

    ALI-JACKSON KAMIL CHIEF LEGAL OFFICER

    • Officer
    		 160,214 2022-01-03 0

    FORESITE CAPITAL MANAGEMENT III, LLC

    FORESITE CAPITAL FUND III, L.P.

    FORESITE CAPITAL MANAGEMENT IV, LLC

    FORESITE CAPITAL FUND IV, L.P.

    FORESITE CAPITAL MANAGEMENT V, LLC

    FORESITE CAPITAL FUND V, L.P.

    TANANBAUM JAMES B.

    • 10% Owner
    		 4,665,553 2021-11-01 0

    GORDON DAVID N. CHIEF MEDICAL OFFICER

    • Officer
    		 147,447 2021-07-13 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD PARTNERS, L.P.

    • 10% Owner
    • POSSIBLE MEMBER OF A 10% GROUP
    		No longer subject to file 2019-06-27 0

    SHANLER STUART CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2019-03-01 0

    POWALA CHRISTOPHER CHIEF REG & DEVELOP OFFICER

    • Officer
    		 272,163 2019-02-01 0

    FAIR BRETT CHIEF COMMERCIAL OFFICER

    • Officer
    		 10,582 2019-02-01 0

    TULLMAN STEPHEN A.

    • Director
    		 571,471 2018-10-04 0

    FMR LLC

    • SEE REMARK 1
    		 No longer subject to file 2017-08-21 0

    BIERLY RICK

    • Director
    		 0 2017-06-15 0

    VIVO VENTURES VII, LLC

    VIVO VENTURES FUND VII, L.P.

    VIVO VENTURES VII AFFILIATES FUND, L.P.

    • 10% Owner
    		 8,925,707 2017-02-28 0

    RA CAPITAL MANAGEMENT, LLC

    KOLCHINSKY PETER

    RA CAPITAL HEALTHCARE FUND LP

    • 10% Owner
    		 No longer subject to file 2016-09-15 0

    CHA ALBERT

    • Director
    		 0 2016-06-29 0

    RA CAPITAL MANAGEMENT, LLC

    KOLCHINSKY PETER

    • 10% Owner
    		 2,314,942 2015-10-19 0

    SOFINNOVA VENTURE PARTNERS VIII, L.P.

    SOFINNOVA MANAGEMENT VIII, L.L.C.

    HEALY JAMES

    AKKARAJU SRINIVAS

    POWELL MICHAEL

    • 10% Owner
    		 2,289,480 2015-10-13 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    WALKER NEAL - Director

    		2023-01-04 18:20:05 -0500 2023-01-04 S 15,000 $14.89 d 1,205,763 direct yes 8.6671 15.7584 15.7584 6 0.0 1

    WALKER NEAL - Director

    		2023-01-04 18:20:05 -0500 2023-01-03 S 23,382 $15.19 d 1,222,381 direct yes 8.6671 15.7584 15.7584 6 0.0 1

    WALKER NEAL - Director

    		2023-01-04 18:20:05 -0500 2023-01-03 S 1,618 $16.16 d 1,220,763 direct yes 8.6671 15.7584 15.7584 6 0.0 1

    MONAHAN JOSEPH - Officer CHIEF SCIENTIFIC OFFICER

    		2022-12-16 16:57:26 -0500 2022-12-15 S 5,000 $15.88 d 96,386 direct yes 3.0137 2.9452 4.726 4 0.0 1

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 22:15:03 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 21:45:03 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 21:15:03 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 20:45:03 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 20:15:03 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 19:45:03 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 19:15:04 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 18:45:03 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 18:15:03 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 17:45:03 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 17:15:04 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 16:45:04 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 16:15:03 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 15:45:03 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 15:15:04 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 14:45:03 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 14:15:03 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 13:45:03 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 13:15:04 UTC 3.9119 0.4081 400000
    ACLARIS THERAPEUTICS INC ACRS 2023-01-31 12:45:03 UTC 3.9119 0.4081 400000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund ACRS -414.0 shares, $-447.12 2019-09-30 N-PORT
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund ACRS -200.0 shares, $-3148.0 2022-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments